NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1110 coverAutoimmunity, Part B Novel Applications of Basic Research Volume 1110 published September 2007
Ann. N.Y. Acad. Sci. 1110: 99–111 (2007). doi: 10.1196/annals.1423.012
Copyright © 2007 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by FERRERA, F.
Articles by FILACI, G.
Search for Related Content
PubMed
PubMed Citation
Articles by FERRERA, F.
Articles by FILACI, G.

Part I. Genetics and Autoimmunity

Gene Vaccination for the Induction of Immune Tolerance

FRANCESCA FERRERAa,c, ANTONIO LA CAVAb, MARTA RIZZIa,c, BEVRA H. HAHNb, FRANCESCO INDIVERIa,c AND GILBERTO FILACIa,c

a Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italyb Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USAc Department of Internal Medicine, University of Genoa, Genoa, Italy

Key Words: genetic immunization • DNA vaccine • tolerance • regulatory lymphocytes • plasmid vectors • viral vectors

Address for correspondence: Gilberto Filaci, Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy. Voice: +39-010-3538984; fax: +39-010-3533025.   gfilaci{at}unige.it

DNA vaccination is a strategy of immunization based on the injection of a gene encoding for a target protein with the goal of eliciting a potentially protective immune response in the host. Compared to traditional immunization procedures, DNA vaccination offers several advantages: increased availability of antigenic peptides because of the endogenous and long-term synthesis of the gene product, improved antigen processing and presentation, possibility of antigen structure modeling through molecular engineering, coexpression of immunologically relevant agents, and low cost of vaccine production. Although the choice of the most appropriate vector for gene transfer may still be controversial, the application of DNA vaccination to the treatment of autoimmune diseases in different experimental animal models has demonstrated the great potential of this procedure for therapeutic purposes. DNA vaccination has been successful in protecting mice from the development of organ-specific autoimmunity (experimental allergic encephalomyelitis (EAE), autoimmune diabetes, experimental arthritis, experimental uveitis) as well as systemic autoimmune disease (systemic lupus erythematosus (SLE), antiphospholipid syndrome). The protection appears to be highly influenced by the capacity of DNA vaccination to modulate immune responses affecting the Th1, Th2 and, importantly, the T cell immunoregulatory arms. We review here the experimental evidence and most recent data supporting the use of DNA vaccination in the induction of immune tolerance.






footerLeft footerRight